摘要
目的探讨贝伐单抗靶向治疗结直肠癌的临床疗效。方法将2010年10月至2012年10月在本院诊治的90例结直肠癌患者随机分成2组,对照组45例,采用卡培他滨治疗;治疗组45例,采用贝伐单抗+卡培他滨治疗。观察比较2组的临床疗效、主要不良反应及肿瘤标志物水平。结果治疗组近期总有效率显著高于对照组(P<0.05);治疗组的主要不良反应发生率与对照组相比差异无统计学意义(P>0.05);治疗组患者治疗后组织多肽特异性抗原、癌胚抗原、癌抗原指标水平均显著性低于对照组(P<0.05)。结论贝伐单抗靶向治疗结直肠癌更有效,毒副作用可耐受。
Objective To investigate the clinical efficacy of bevacizumab targeted therapy of colorectal cancer.Methods The ninety colorectal cancer patients admitted to hospital from October 2010 to October 2012 were randomly divided into control group （n =45） and treatment group （n =45）.The control group was given capecitabine,and the treatment group was given bevacizumab in addition to capecitabine.The clinical efficacy,adverse reactions and levels of tumor markers of both groups were observed and compared.Results The total efficacy rate of the treatment group was significantly higher than that of the control group （P ＜ 0.05）.The incidence of adverse reactions in the treatment group was similar to that of the control group （P ＞ 0.05）.The levels of tissue polypeptide specific antigen,carcinoembryonic antigen,and carcinomic antigen242 of the treatment group after treatment were significantly lower than those of the control group （P ＜ 0.05）.Conclusion The clinical application of bevacizumab targeted therapy of colorectal cancer can more significantly improve clinical efficacy,and the fibrinolytic system and arterial blood gas levels,relieve difficulty in breathing symptoms,and the adverse reactions can be tolerated.
出处
《实用临床医药杂志》
CAS
2013年第16期90-91,96,共3页
Journal of Clinical Medicine in Practice
关键词
结直肠癌
贝伐单抗
靶向治疗
colorectal cancer
bevacizumab
targeted therapy
